{"generic":"Rabies Vaccine","drugs":["Imovax Rabies","Rabavert","Rabies Vaccine"],"mono":{"0":{"id":"501680-s-0","title":"Generic Names","mono":"Rabies Vaccine"},"1":{"id":"501680-s-1","title":"Dosing and Indications","sub":{"0":{"id":"501680-s-1-4","title":"Adult Dosing","mono":"<ul><li>Rabies vaccine adsorbed is no longer available for rabies preexposure or postexposure prophylaxis.<\/li><li>Rabies vaccine preparations for intradermal use are no longer available in the United States.<\/li><li>assistance with questions about rabies prophylaxis can be obtained from the local health department or the rabies information line at the National Center for Infectious Diseases, CDC at (404) 639-1050.<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (not previously vaccinated, immunocompetent) 1 mL IM x 4 doses, one each on days 0, 3, 7, and 14 in conjunction with the administration of 1 dose of human rabies immune globulin (HRIG) on day 0; begin with the administration of HRIG 20 International Units\/kg IM<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (not previously vaccinated, immunocompromised) 1 mL IM x 5 doses, one each on days 0, 3, 7, 14 and 28 in conjunction with the administration of 1 dose of human rabies immune globulin (HRIG) on day 0; begin with the administration of HRIG 20 International Units\/kg IM<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (previously vaccinated,  immunocompetent and immunocompromised) 1 mL IM x 2 doses, one each on day 0 and 3; human rabies immune globulin should not be given<\/li><li><b>Rabies, Preexposure; Prophylaxis:<\/b> (primary immunization) 1 mL IM x 3 doses, one each on days 0, 7, and 21 or 28<\/li><li><b>Rabies, Preexposure; Prophylaxis:<\/b> (booster immunization) 1 mL IM as needed, to maintain a serum titer greater than 1:5 serum dilution by the rapid fluorescent inhibition test<\/li><\/ul>"},"1":{"id":"501680-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Rabies vaccine adsorbed is no longer available for rabies preexposure or postexposure prophylaxis.<\/li><li>Rabies vaccine preparations for intradermal use are no longer available in the United States.<\/li><li>assistance with questions about rabies prophylaxis can be obtained from the local health department or the rabies information line at the National Center for Infectious Diseases, CDC at (404) 639-1050.<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (not previously vaccinated, immunocompetent) 1 mL IM x 4 doses, one each on days 0, 3, 7, and 14  in conjunction with the administration of 1 dose of human rabies immune globulin (HRIG) on day 0; begin with the administration of HRIG 20 International Units\/kg IM<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (not previously vaccinated, immunocompromised) 1 mL IM x 5 doses, one each on days 0, 3, 7, 14 and 28 in conjunction with the administration of 1 dose of human rabies immune globulin (HRIG) on day 0; begin with the administration of HRIG 20 International Units\/kg IM<\/li><li><b>Rabies, Postexposure; Prophylaxis:<\/b> (previously vaccinated, immunocompetent and immunocompromised) 1 mL IM x 2 doses, one each on day 0 and 3; human rabies immune globulin should not be given<\/li><li><b>Rabies, Preexposure; Prophylaxis:<\/b> (primary immunization) 1 mL IM x 3 doses, one each on days 0, 7, and 21 or 28<\/li><li><b>Rabies, Preexposure; Prophylaxis:<\/b> (booster immunization) 1 mL IM as needed, to maintain a serum titer greater than 1:5 serum dilution by the rapid fluorescent inhibition test<\/li><\/ul>"},"3":{"id":"501680-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Rabies vaccine adsorbed is no longer available for rabies preexposure or postexposure prophylaxis [1].<\/li><li>Rabies vaccine preparations for intradermal use are no longer available in the United States [1].<\/li><li>Rabies, Postexposure; Prophylaxis<\/li><li>Rabies, Preexposure; Prophylaxis<\/li><\/ul>"}}},"3":{"id":"501680-s-3","title":"Contraindications\/Warnings","sub":[{"id":"501680-s-3-9","title":"Contraindications","mono":"<ul><li>(preexposure vaccination) anaphylaxis or life-threatening systemic hypersensitivity reaction to rabies vaccine or any component of the vaccine<\/li><li>(postexposure vaccination) no specific contraindications<\/li><\/ul>"},{"id":"501680-s-3-10","title":"Precautions","mono":"<ul><li>anaphylaxis to rabies vaccine or any component, history of; use for postexposure vaccination only if no alternative product can be found, have epinephrine (1:1000) and other medical equipment and emergency supplies available; monitoring recommended<\/li><li>anaphylaxis, encephalitis (including death), and meningitis have been reported (RanAvert(R))<\/li><li>antibiotics present in vaccine; although the concentrations are very small, use caution in patients with known hypersensitivity to these components<\/li><li>concomitant immunosuppressive agents should be avoided during postexposure vaccination unless essential for treatment of other conditions; if concomitant use is required, monitoring for adequate vaccine response recommended<\/li><li>convalescent, sick, or in incubation stage of an infectious disease; postpone preexposure vaccination<\/li><li>gluteal region injection, not recommended; lower neutralizing antibody titers may result<\/li><li>human blood derived albumin is present in the vaccine; remote risk for viral disease transmission and theoretical risk of the transmission of Creutzfeldt-Jakob disease<\/li><li>immune-compromised patients; development of active immunity may be impaired; monitoring for adequate vaccine response recommended<\/li><li>IM use only; should not be administered subQ, IV, or intradermally; systemic reactions including shock may occur after IV injection<\/li><li>neurologic illness resembling Guillian-Barre syndrome has been reported rarely<\/li><li>neuroparalytic illness (ie, encephalitis, transient paralysis, Guillian-Barre syndrome, myelitis, retrobulbar neuritis, and multiple sclerosis) has been temporarily associated with the vaccine, with complete resolution after 12 weeks<\/li><li>serum sickness type reaction; have been reported with preexposure booster doses<\/li><li>report all serious systemic neuroparalytic or anaphylactic reactions to the Vaccine Adverse Effects Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"501680-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"501680-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"501680-s-4","title":"Drug Interactions","sub":{"1":{"id":"501680-s-4-14","title":"Major","mono":"<ul><li>Chloroquine (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><\/ul>"}}},"5":{"id":"501680-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (up to 84%), Rash<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (human diploid cell rabies vaccine, 20%), Nausea (human diploid cell rabies vaccine, 20%)<\/li><li><b>Immunologic:<\/b>Localized enlarged lymph nodes (15%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia, Myalgia (20% to 53%)<\/li><li><b>Neurologic:<\/b>Dizziness (10% to 20%), Headache (chick embryo rabies vaccine, 10% to 52%; human diploid cell rabies vaccine, 20% to 45%)<\/li><li><b>Other:<\/b>Influenza-like symptoms, Malaise (15% to 25%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Encephalitis, Guillain-Barr  syndrome<\/li><li><b>Other:<\/b>Transfusion reaction due to serum protein reaction (up to 7%)<\/li><\/ul>"},"6":{"id":"501680-s-6","title":"Drug Name Info","sub":{"0":{"id":"501680-s-6-17","title":"US Trade Names","mono":"<ul><li>Imovax Rabies<\/li><li>Rabavert<\/li><\/ul>"},"2":{"id":"501680-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"501680-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"501680-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"501680-s-7","title":"Mechanism Of Action","mono":"Rabies vaccine is an inactivated virus from the fixed-virus strain Flury LEP that aids in preexposure and postexposure prophylaxis against rabies infection. Its protective action against rabies infection may be associated with its ability to boost immunity by increasing the anti-rabies antibody titer above the minimum accepted protective titer.<br\/>"},"9":{"id":"501680-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(injection) for IM or intradermal use only; do not inject intravascularly or subcutaneously<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>adults and older children (2 years of age and older); administer into the deltoid muscle<\/li><li>infants and small children (under 2 years of age); administer into the anterolateral aspect of the thigh<\/li><li>avoid gluteal area due to reduced antibody formation <\/li><\/ul><\/li><\/ul>"},"11":{"id":"501680-s-11","title":"How Supplied","mono":"<ul><li><b>Imovax Rabies<\/b><br\/>Intramuscular Powder for Suspension: 2.5 IU<br\/><\/li><li><b>RabAvert<\/b><br\/>Intramuscular Powder for Suspension: 2.5 IU<br\/><\/li><\/ul>"},"13":{"id":"501680-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause localized enlarged lymph nodes, myalgia, dizziness, headache, or malaise.<\/li><li>Advise patient to report signs\/symptoms of encephalitis.<\/li><li>Counsel patient on dosing schedule, depending on situation and need for this vaccination.<\/li><li>Advise patient to call healthcare professional if a treatment is missed, as drug should be given on a fixed schedule.<\/li><\/ul>"}}}